Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 28, 2006; 12(16): 2569-2573
Published online Apr 28, 2006. doi: 10.3748/wjg.v12.i16.2569
Table 1 Characteristics of the intention-to-diagnose population in the placebo and rabeprazole groups (n, mean ± SD)
Placebo(n = 39)Rabeprazole(n = 33)Pvalue
Men/women (%)46/5433/670.269
Mean age (yr)(mean ± SD) 47.1±11.849.1±11.90.4
BMI (kg/m2) (mean ± SD)25.6 ± 4.426.1±5.20.8
Smoker (%)17.930.30.219
Previous endoscopy (%)33.330.30.783
Time from first symptoms1 (mo)24.3 ± 51.520.2 ± 27.00.956
Post-prandial symptoms (%)30.833.30.232
Nocturnal symptoms (%)12.815.10.232
Hiatus hernia (%)47.427.30.082
Esophagitis (%)30.833.30.816
Barrett's oesophagus (%)2.66.10.474
Diagnosis of GERD2 (%)67.662.10.642